(238 days)
Not Found
No
The summary describes a mechanical compression device and does not mention any AI or ML components or functionalities.
Yes
The device is indicated for the treatment and prevention of various medical conditions, such as lymphedema, DVT, and edema, which are typical uses for a therapeutic device.
No
The device description clearly states "The ProAct 1 or ProAct with gel device is a gradient sequential compression device used in the treatment of lymphedema." and the Intended Use/Indications for Use section lists conditions like "Lymphedema - primary and secondary", "Prevention of venous stasis", and "Prevention of Deep Vein Thrombosis (DVT)", all indicating a treatment function rather than a diagnostic one.
No
The device description explicitly lists hardware components: a control unit, compressible limb sleeves with gel, and pneumatic connecting tubes. This indicates it is a physical medical device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly describes a device used for physical therapy and treatment of conditions like lymphedema, venous stasis, DVT prevention, and edema. These are all conditions treated externally on the body.
- Device Description: The device description details a compression device with a control unit, sleeves, and connecting tubes. This is consistent with a physical therapy or medical device used for external application.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or compatibility testing.
IVD devices are specifically designed to be used in vitro (outside the body) to analyze biological samples. This device operates in vivo (on the body) through external compression.
N/A
Intended Use / Indications for Use
The ProAct with Gel is a prescriptive device indicated for:
- . Lymphedema - primary and secondary
- . Prevention of venous stasis
- Prevention of Deep Vein Thrombosis (DVT) .
- Edema following trauma and sports injuries .
- Post immobilization edema .
Product codes (comma separated list FDA assigned to the subject device)
JOW
Device Description
The ProAct with gel device is a gradient sequential compression device used in the treatment of lymphedema. The ProAct with gel uses the same powered control device that delivers gradient sequential compression pressure to the chambered compressible limb sleeves. The device is composed of three components:
- Lightweight, portable control unit .
- Compressible limb sleeves with gel in 3 sizes for arms and legs (Brookwood 70 denier MD Nylon . and DAF Breathable 270 Nylon)
- . Pneumatic connecting tubes
- . The subject device includes sleeves with Nosocryl D60 gel in the chambers.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Arms and legs
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.5800 Compressible limb sleeve.
(a)
Identification. A compressible limb sleeve is a device that is used to prevent pooling of blood in a limb by inflating periodically a sleeve around the limb.(b)
Classification. Class II (performance standards).
0
Koszz43
510(k) Summary
(1) Contact Information
This 510(k) is being submitted by Joseph Azary on behalf of ProAct.
Submitter / Regulatory Consultant: Joseph Azary, 543 Long Hill Avenue, Shelton, CT 06484, Tel: 203-944-9320, Fax: 203-944-9317
Applicant / Sponsor: ProAct Inc. (Professional Advanced Compression Therapy Inc.), 1 Stone Eiver Road, Laurel Springs, New Jersey 08021, FDA Establishment Registration pending,
(2) Device Information
The device is classified as Class II under IRP and JOW, 21 CFR 890.5650 and 21 CFR 870.5800.
The ProAct 1 or ProAct with gel device is a gradient sequential compression device used in the treat ment of lymphedema.
The ProAct with gel is a modification to the ProAct 1 device that received FDA marketing clearance under 510(k) K003909_
The ProAct with gel uses the same powered control device that delivers gradient sequential compression pressure to the chambered compressible limb sleeves. The device is composed of three components:
- Lightweight, portable control unit .
- Compressible limb sleeves with gel in 3 sizes for arms and legs (Brookwood 70 denier MD Nylon . and DAF Breathable 270 Nylon)
- . Pneumatic connecting tubes
The control unit specifications and limb sleeve specifications have been included in Annex 1.
- . The subject device includes sleeves with Nosocryl D60 gel in the chambers.
The gel was added to address market requests.
1
The gel does not make direct contact with the patient. The gel will be enclosed within the Nylon cham ber. In the event the Nosocryl material leaked it is believed to have minimal safety concerns. Nosocryl is a super absorbent polymer material that has been used in disposable diapers over the last 20 years and also in feminine care products, adult incontinence pads, and in absorbent pads used in food package ing. Nosocryl has the following toxicological characteristics.
- Practically no harm to animals during acute toxicity testing. .
- Practically no harm to animals during skin contact and eye contact testing. .
- The material is not a skin sensitizer. .
- Studies of prolonged inhalation in animals have not shown systemic effects. .
- Experimental data found the material not to be genotoxic. .
- (3) Trade or Proprietary Name: ProAct with Gel or ProAct 1
Common, Usual, and Classification Name:
- . Gradient Sequential Compression Pump
- Powered Inflatable Tube Massager. .
(4) Predicate Devices:
The predicate devices are identified as the following: ProAct 1 - 510(k) K003909
The difference with the ProAct with gel is as follows:
- . The sleeves now contain chambers with Nosocryl D60 gel.
The material is non-toxic and has been used for other medical applications.
(5) Intended Use:
The ProAct with Gel is a prescriptive device indicated for:
- . Lymphedema - primary and secondary
- . Prevention of venous stasis
- Prevention of Deep Vein Thrombosis (DVT) .
- Edema following trauma and sports injuries .
- Post immobilization edema .
- (6) Technological Characteristics: The technological characteristics of the device remain the same. The gel is added to the chambers. The indications for use, power unit, and features of the device remain the same.
- (7) Conclusion: We believe the differences are minor and conclude that the subject device is as safe and effective as the predicate devices.
2
Image /page/2/Picture/2 description: The image shows the address of the Food and Drug Administration. The address is 9200 Corporate Boulevard, Rockville MD 20850. The text is black and the background is white.
APR 1 2 2006
Azary Technologies, LLC c/o Mr. Joseph M. Azary III President 543 Long Hill Avenue Shelton, CT 06484
Re: K052243
ProAct with gel / ProAct 1 Regulation Number: 21 CFR 870.5800 Regulation Name: Compressible limb sleeve Regulatory Class: Class II Product Code: JOW Dated: January 12, 2006 Received: January 17, 2006
Dear Mr. Azary:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 - Mr. Joseph M. Azary III
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
Bimmuma for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known):
Device Name: ProAct with gel / ProAct 1
Indications For Use:
The ProAct with Gel is a prescriptive device indicated for:
- . Lymphedema - primary and secondary
- Prevention of venous stasis .
- Prevention of Deep Vein Thrombosis (DVT) .
- Edema following trauma and sports injuries .
- Post immobilization edema .
× Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
B.H.mmetma
sion Sign-Off) Division of Cardiovascular Devices 510(k) Number
Page 1 of /